Feature|Articles|August 16, 2024
- Pharmaceutical Executive: July/August 2024
- Volume 44
- Issue 7/8
Pharmaceutical Executive: July/August 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive July/August 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 2 years ago
An AI Pulse Checkalmost 2 years ago
Divergent Paths: Pharm Exec Profiles Five Recent Drug Launchesalmost 2 years ago
A Promising Option: Exxuaalmost 2 years ago
Opening the Door: Omvohalmost 2 years ago
'Marked’ for Stardom?: Truqapalmost 2 years ago
Branching Off: Wegovyalmost 2 years ago
A Formidable First: Winrevairalmost 2 years ago
The Future of Launch Excellence is Generative AIalmost 2 years ago
From Potential to Value: Carving a Slice of the CGT ‘PIE'almost 2 years ago
Big Bets, Bold StepsAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
5